JK Science
Effect of Three Different Doses of Dexmedetomide (5 mcg, 7.5 mcg and 10 mcg) as an Adjuvant to Bupivicaine in Spinal Anesthesia for Total Abdominal Hysterectomies: A Prospective Randomized Study
By Ashufta Rasool, Kunal Sharma, Rumani Ruku and 1 others.
Abstract
Background
Dexmedetomidine, a selective 2-adrenoceptor agonist, has emerged as a promising adjuvant in spinal anesthesia. This study aimed to compare the efficacy and safety of three intrathecal dexmedetomidine doses (5, 7.5, and 10 mcg) as adjuvants to 0.5% hyperbaric bupivacaine in patients undergoing total abdominal hysterectomy.
Methods
Ninety female patients (ASA I–II, aged 18–60) undergoing elective hysterectomy under spinal anesthesia were randomized into three equal groups. All received 0.5% hyperbaric bupivacaine with either 5 mcg (GROUP D5), 7.5 mcg (GROUP D7.5), or 10 mcg (GROUP D10) of dexmedetomidine intrathecally. Primary outcomes included onset and duration of sensory and motor block. Hemodynamic stability and adverse effects were monitored.